Species |
Rat |
Protein Construction |
VEGF164 (Ala27-Arg190) Accession # P16612-2 |
|
Purity |
> 95% as analyzed by SDS-PAGE > 95% as analyzed by HPLC |
Endotoxin Level |
< 0.2 EU/μg of protein by gel clotting method |
Biological Activity |
ED50 < 4.0 ng/ml, measured in a cell proliferation assay using HUVEC cells, corresponding to a specific activity of >2.5 × 105 units/mg |
Expression System |
CHO |
Apparent Molecular Weight |
35~48 kDa, on SDS-PAGE under non-reducing conditions. |
Formulation |
Lyophilized after extensive dialysis against PBS. |
Reconstitution |
It is recommended that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute the lyophilized powder in ddH₂O or PBS up to 100 μg/ml. |
Storage & Stability |
Upon receiving, this product remains stable for up to 6 months at lower than -70°C. Upon reconstitution, the product should be stable for up to 1 week at 4°C or up to 3 months at -20°C. For long term storage it is recommended that a carrier protein (example 0.1% BSA) be added. Avoid repeated freeze-thaw cycles. |
ED₅₀< 4 ng/ml, measured in a cell proliferation assay using HUVEC cells, corresponding to a specific activity of >2.5 x 10⁵ units/mg
Target Background |
Vascular Endothelial Growth Factor A164 (VEGF-A164), a member of the cysteine knot growth factor, is one of major isoforms of VEGF-As. VEGF-As are endothelial cell-specific mitogens with angiogenic and vascular permeability-inducing properties. During maturation, rat VEGF-A is alternatively spliced to generate rVEGF-A120, rVEGF-A164 and rVEGF-A188 which correspond to hVEGF-A121, hVEGF-A165 and hVEGF-A189 in human, respectively (the numbers designate the amino acid residues). The active form of rVEGF-A164 is either a homodimeric or heterodimeric polypeptides which bind to the transmembrane tyrosine kinases receptors FLT1, FLK1 or KDR or to the non-tyrosine kinase neuropilin receptors NRP1/2. |
Synonyms |
Folliculostellate cell-derived growth factor; Glioma-derived endothelial cell mitogen; VEGF-164; Vascular Permeability Factor; VPF |
For laboratory research use only. Direct human use, including taking orally and injection and clinical use are forbidden.